NCT04203615

Brief Summary

Hypokinetic dysarthria (HD) is common in Parkinson's disease (PD) patients and responds only partially to pharmacotherapy and surgery. The investigators will explore long-term effects of repetitive transcranial magnetic stimulation (rTMS) applied over right superior temporal gyrus, brain area known to be engaged in the feedback control of voiced speech. The project results will allow for the identification of potential therapeutic effects of rTMS as a tool that could contribute to the speech therapy of HD in PD patients. The results will also enhance our understanding of brain mechanisms underlying specific long-term effects of rTMS.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
39

participants targeted

Target at P25-P50 for not_applicable parkinson-disease

Timeline
Completed

Started Jul 2019

Shorter than P25 for not_applicable parkinson-disease

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2019

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

December 9, 2019

Completed
9 days until next milestone

First Posted

Study publicly available on registry

December 18, 2019

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 30, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 30, 2020

Completed
Last Updated

September 2, 2020

Status Verified

September 1, 2020

Enrollment Period

7 months

First QC Date

December 9, 2019

Last Update Submit

September 1, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Changes in score of the 3F Test (the unabbreviated title- "the 3F Test Dysarthric Profile")

    The 3F Test Dysarthric Profile enables clinicians to characterize a wide range of signs and symptoms of dysarthria. The minimum value of this scale is 0 (anarthria), the maximum value is 90 (no disorder). Higher scores of this scale mean better outcome. This test will be administrated by speech pathologist.

    On the beginning of the study, after completion of two weeks stimulation, 4,8 and 12 weeks after completion of stimulation sessions.

Secondary Outcomes (1)

  • Resting state

    On the beginning of the study, after completion of two weeks stimulation, 4,8 and 12 weeks after completion of stimulation sessions.

Study Arms (2)

PD patients with real rTMS

ACTIVE COMPARATOR

Patients will receive real rTMS in a two weeks long sessions (10 sessions).

Device: Transcranial magnetic stimulation- real rTMS

PD patients with sham rTMS

SHAM COMPARATOR

Patients will receive sham rTMS in a two weeks long sessions (10 sessions).

Device: Transcranial magnetic stimulation- sham rTMS

Interventions

Transcranial magnetic stimulation- sham figure-eight coil will be used for stimulation. This sham coil will generate only clicking noise and will not generate any magnetic field.

PD patients with sham rTMS

Transcranial magnetic stimulation- figure-eight coil will be used for stimulation. 1 Hz stimulation, 100% of Resting Motor Threshold will be used.

PD patients with real rTMS

Eligibility Criteria

Age50 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients with clinically established PD (Postuma et al. 2016)

You may not qualify if:

  • psychiatric disorders, including major depression, hallucinations
  • any MRI-incompatible metal in the body
  • epilepsy
  • lack of cooperation
  • presence of dementia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Central European Institute of Technology

Brno, Czechia

Location

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: A two parallel group, randomized, placebo controlled design will be used. Twenty PD patients will be stimulated in a two weeks long therapeutical sessions (10 sessions). Other twenty PD patients will be stimulated with the same protocol using sham stimulation.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 9, 2019

First Posted

December 18, 2019

Study Start

July 1, 2019

Primary Completion

January 30, 2020

Study Completion

January 30, 2020

Last Updated

September 2, 2020

Record last verified: 2020-09

Locations